Page 99 - Demo

especialmente: precisa (a trav%u00e9s de pruebas m%u00e1s precisas y concluyentes yde una mejor selecci%u00f3n de los tratamientos), perif%u00e9rica (con una tendenciahacia la hospitalizaci%u00f3n domiciliaria y a la aplicaci%u00f3n de la telemedicina),poliprofesional (integradora de los conocimientos de profesionales formadosen distintos %u00e1mbitos) y placentera (mejor calidad de vida, no s%u00f3lo mayoresperanza de vida) (66). 5. RefeReNCIAs1. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, andprogress. Fertil. Steril. 2018; 109(6):952-963. 2. Parodi A, Rudzinska M, Leporatti S, Anissimov Y and Zamyatnin AA Jr. Smartnanotheranostics responsive to pathological stimuli. Front. Bioeng.Biotechnol. 2020; 8:503. 3. Li X, Gao Y, Li H, Majoral JP, Shi X, Pich A. Smart and bioinspired systems forovercoming biological barriers and enhancing disease theranostics. Prog.Mater. Sci. 2023; 140:101170. 4. Li M, Hu X, Zhao Y, Jiao N. An overview of recent progress in micro/nanorobotsfor biomedical applications. Adv. Mater. Technol. 2023; 8:2201928. 5. Haga SB, Mills R, Moaddeb J. Pharmacogenetic information for patients on druglabels. Pharmgenomics. Pers. Med. 2014;7: 297%u2013305. 6. Sun J, Han JDJ, Chen W. Exploring the relationship among Alzheimer%u2019s disease,aging and cognitive scores through neuroimaging-based approach. Sci. Rep.2024; 14:27472.7. Krause W. Delivery of diagnostic agents in computed tomography. Adv. DrugDeliv. Rev. 1999; 37:159 %u2013173.8. van der Molen AJ, Dekkers IA, Geenen RWF, Bellin MF, Bertolotto M, BrismarTB, Correas JM, Heinz-Peer G, Mahnken AH, Quattrocchi CC, Radbruch A,Reimer P, Roditi G, Romanini L, Sebasti%u00e0 C, Stacul F, Clement O. Waitingtimes between examinations with intravascularly administered contrastmedia: a review of contrast media pharmacokinetics and updated ESURContrast Media Safety Committee guidelines. Eur. Radiol. 2024;34:2512%u20132523.9. Courchesne M, Manrique G, Bernier L, Moussa L, Cresson J, Gutzeit A, FroehlichJM, Koh DM, Chartrand-Lefebvre C, Matoori S. Gender differences inpharmacokinetics: A perspective on contrast agents. ACS Pharmacol. Transl.Sci. 2024;7 (1):8-17. 10. Xue Y, Gao Y, Meng F, Luo L. Recent progress of nanotechnology-basedtheranostic systems in cancer treatments. Cancer Biol. Med. 2021;18(2):336%u201351.11. Jiang Z, Zhang M, Li P, Wang Y, Fu Q. Nanomaterial-based CT contrast agentsand their applications in image-guided therapy. Theranostics 2023;13(2):483-509.12. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv. DrugDeliv. Rev. 2012;64 (13):1394-1416.97 Nanomateriales y NanomedicinaMar%u00eda Vallet, Antonio J. Salinas